<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198080</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Bone-003</org_study_id>
    <nct_id>NCT01198080</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of Bone Marrow Derived Cd133+ Cells in Patient With Osteonecrosis of Femoral Head</brief_title>
  <official_title>Bone Marrow Derived CD133+ Stem Cells Transplantation in Femoral Head Osteonecrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Avascular necrosis is a disease where there is cellular death (necrosis) of bone components&#xD;
      due to interruption of the blood supply. Without blood, the bone tissue dies and the bone&#xD;
      collapses. If avascular necrosis involves the bones of a joint, it often leads to destruction&#xD;
      of the joint articular surfaces. Avascular necrosis is especially common in the hip joint. A&#xD;
      variety of methods are now used to treat avascular necrosis the most common being the total&#xD;
      hip replacement, or THR.A new, more promising treatment is hip resurfacing or metal on metal&#xD;
      (MOM) resurfacing.Another treatment is utilization of bone marrow derived stem cells.these&#xD;
      stem cells can provide angiogenic factors and osteogenic cytokine to improve angiogenesis and&#xD;
      bone formation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A vascular necrosis of femoral head is a debilitating disease resulting from interruption of&#xD;
      blood supply to the bone. This pathologic process results in the death of marrow and&#xD;
      osteocytes and, in its final stage, femoral head collapse. The most widespread treatment in&#xD;
      the early stage of this disease is core decompression. This surgical procedure involves&#xD;
      drilling into the femoral neck through the necrotic area, which reduces pressure within the&#xD;
      bone and allows more blood vessels to form. This study is designed to evaluate the clinical&#xD;
      safety and efficacy of CD133+ enriched bone marrow infusion adjacent with core decompression&#xD;
      in patients with a vascular necrosis of femoral head . Patients will undergo core&#xD;
      decompression followed by CD133+cell infusion into the cored area. Clinical assessment&#xD;
      includes a MRI, Harries Hip Score,SF36, Visual Analogue Scale(VAS), and the WOMAC&#xD;
      osteoarthritis Index.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of bone marrow derived CD133+ cells transplantation</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation safety of bone marrow CD133+ cells transplantation in patients with osteonecrosis of femoral head</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improve patient quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate the ability of bone marrow derived CD133+ cells to improve patient quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decrease hip articular change</measure>
    <time_frame>24 month</time_frame>
    <description>evaluate the ability of bone marrow derived CD133+ cells to decrease hip articular change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate side effects of bone marrow derived CD133+ cells transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Osteonecrosis</condition>
  <arm_group>
    <arm_group_label>femoral osteonecrosis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patientswith femoral head osteonecrosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD133+ cells</intervention_name>
    <description>bone marrow derived CD133+ cells injection with core compression</description>
    <arm_group_label>femoral osteonecrosis patients</arm_group_label>
    <other_name>cell injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Upenn (Steinberg) classification of osteonecrosis, inclusive of Stages IIB and IIC.&#xD;
             Diagnosis will be based on magnetic resonance imaging (MRI).&#xD;
&#xD;
          -  Modified index of necrotic extent &lt; 40&#xD;
&#xD;
          -  Idiopathic and non-idiopathic osteonecrosis.&#xD;
&#xD;
          -  No infection in affected bones at the time of surgery.&#xD;
&#xD;
          -  Patient competent to give informed consent.&#xD;
&#xD;
          -  Normal organ and marrow function defined as:&#xD;
&#xD;
               -  Leukocytes ≥ 3000/µL;&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1500/µL;&#xD;
&#xD;
               -  Platelets ≥ 140,000/µL;&#xD;
&#xD;
               -  Serum AST (SGOT)/ALT (SGPT) &lt; 2.5 X institutional standard range;&#xD;
&#xD;
               -  Serum creatinine within normal limits, based on clinical laboratory normal range.&#xD;
&#xD;
          -  Female patients not pregnant or lactating.&#xD;
&#xD;
          -  Patients with a history of corticosteroids or on active therapy, will only be eligible&#xD;
             for enrollment if corticosteroid use is suspended for 1 month prior and 6 months after&#xD;
             cell therapy and surgery.&#xD;
&#xD;
          -  Patients who have been treated with oral bisphosphonates are eligible for the trial if&#xD;
             treatment was stopped at least 6 months prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stages IA, IB, IC, IIA, IIIA or more severe femoral head osteonecrosis, primarily&#xD;
             based on diagnosis by MRI.&#xD;
&#xD;
          -  Flattening of the femur head (UPenn Stage IV) or articular cartilage collapse at the&#xD;
             time of core decompression surgery.&#xD;
&#xD;
          -  Septic arthritis; stress fracture, or non-osteonecrosis metabolic bone diseases (e.g.,&#xD;
             Paget's disease of bone, osteogenesis imperfecta, primary hyperparathyroidism, fibrous&#xD;
             dysplasia [monostotic, polyostotic McCune-Albright syndrome] and osteopetrosis).&#xD;
&#xD;
          -  Any active bisphosphonate treatment or any history of intravenous (IV) treatment&#xD;
&#xD;
          -  HIV, syphilis, positive at time of screening.&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection at the time of screening&#xD;
&#xD;
          -  Known allergies to protein products (horse or bovine serum, or porcine trypsin).&#xD;
&#xD;
          -  Patients who will require continuous, systemic, high dose corticosteroid therapy (more&#xD;
             than 7.5 mg/day) within 6 months after surgery.&#xD;
&#xD;
          -  received chemotherapy, radiotherapy or immunotherapy in the past 2 years.&#xD;
&#xD;
          -  Immunodeficiency diseases.&#xD;
&#xD;
          -  Participation in another clinical study in the past 30 days or concurrent&#xD;
             participation in another clinical trial.&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 2 drinks/day (1 drink = 5 oz [150 mL]&#xD;
             of wine or 12 oz [360 mL] of beer or 1.5 oz [45 mL] of hard liquor) within 6 months of&#xD;
             screening and/or history of illicit drug use.&#xD;
&#xD;
          -  MRI-incompatible internal devices (pacemakers, aneurysm clips, etc)&#xD;
&#xD;
          -  Body mass index (BMI) of 40 Kg/m2 or greater&#xD;
&#xD;
          -  Patients unable to tolerate general anesthesia defined as an American Society of&#xD;
             Anesthesiologists (ASA) criteria of &gt; 2&#xD;
&#xD;
          -  Patients with poorly controlled diabetes mellitus (HbA1C &gt; 8%), or with peripheral&#xD;
             neuropathy, or known concomitant vascular problems.&#xD;
&#xD;
          -  Patients receiving treatment with hematopoietic growth factors or anti-vasculogenesis&#xD;
             or anti-angiogenesis treatment&#xD;
&#xD;
          -  Traumatic osteonecrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmad Vosough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Board scientific</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of regenerative medicine center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Reza Baghban Eslami, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Board Sientific</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mohssen Emadeddin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopedic Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.royaninstitute.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avascular osteonecrosis,CD133+,core decompression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

